ArticleClinical kidney journal2025
Comparing hemodialysis and hemodiafiltration performance with and without hemoadsorption.
Article in Clinical kidney journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Enhanced cognitive outcomes with triple-mode dialysis in kidney failure: role of protein-bound toxin clearance.Renal failure · 2025Trial
- Comparing Ibuprofen and Loop Diuretics for Protein-Bound Uremic Toxins Clearance During Hemodialysis.Kidney international reports · 2026Article
- Hemodiafiltration in Dialysis Practice: Global Adoption, Toxin Clearance, Inflammation Control, and Clinical Safety.Toxins · 2026Review
- Comparable Efficacy of Medium Cut-Off Dialysis Plus HA130 Hemoadsorption and Postfilter Hemodiafiltration in Removing Protein-Bound Uremic Toxins.Kidney medicine · 2026Article
- Dialysis vintage modifies the effect of adsorption-based therapies on protein-bound toxin clearance.Frontiers in cell and developmental biology · 2026Article
- Comparison of 2-hour versus 4-hour hemoadsorption combined with hemodialysis (HAHD): an in vitro and prospective clinical evaluation.Renal failure · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: New cartridges have been developed using the latest resins for hemoadsorption (HA). When used alongside dialyzers, these cartridges may enhance the removal of certain uremic toxins achieved with classical diffusion and convection. This study aimed to assess the elimination of a wide range of molecular weight solutes, including protein-bound uremic toxins, in hemodialysis (HD) and postdilution hemodiafiltration (HDF) treatments. Methods: A prospective study was conducted involving 20 patients who underwent six dialysis sessions with routine treatment parameters maintenance, while only the dialysis modality was modified. The modalities included low-flux HD (LFHD), LFHD-HA, high-flux HD (HFHD), HFHD-HA, HDF and HDF-HA. Results: Urea and creatinine reduction ratios (RR) were higher in HDF treatments (with or without HA) versus LFHD and HFHD treatments. In the same treatment modality, the addition of HA did not modify the small molecules removal. The combination of LFHD-HA showed increased RR of β Conclusions: The results confirmed the superiority of postdilution HDF over LFHD and HFHD, as well as HFHD over LFHD. Incorporating adsorption into the standard LFHD diffusion significantly enhanced the removal of uremic toxins, whose clearance is restricted by the dialyzer's pore size. In contrast, incorporating adsorption alongside the typical diffusion and convection resulted in a modest enhancement in HFHD, with similar outcomes for HDF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.